- Question from MasonG: Any new options for triple-negative breast cancer that have shown real promise?
- Answers - Eric Winer, M.D. The option that is the most encouraging is the PARP inhibitor Iniparib. In a preliminary study, it enhanced the effectiveness of chemotherapy and seemed to prolong survival. A more definitive study has been completed and we are waiting for the results.
The Ask-the-Expert Online Conference called Updates From the 2010 San Antonio Breast Cancer Symposium featured Eric Winer, M.D. and Marisa Weiss, M.D. answering your questions about the latest updates on breast cancer risk, screening, and treatment in early and metastatic breast cancer.
Editor's Note: This conference took place in December 2010.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.